Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 5,963

Document Document Title
WO/2012/097093
The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used...  
WO/2012/095853
The present invention relates to a pharmaceutical composition for oral administration which comprises an active pharmaceutical ingredient ("API") selected from SIP receptor modulators and agonists, wherein the composition is adapted to p...  
WO/2012/097330
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  
WO/2012/096458
Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for prepar...  
WO/2012/097057
Compositions, methods and kits are provided for modulating the trans-differentiation of cells for example muscle satellite cells. The compositions, methods and kits include a modulator of trans-differentiation of the muscle satellite cel...  
WO/2012/097330
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  
WO/2012/097093
The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used...  
WO/2012/094636
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory rec...  
WO/2012/092035
Disclosed are methods utilizing beta-hydroxy-beta-methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prev...  
WO/2012/091571
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/091549
Composition comprising at least two components, more preferably at least three com- ponents, more preferably at least four components, selected from the group of (i) a nu- cleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid sele...  
WO/2012/088597
Use of nitric oxide amino acid esters to treat muscular or neuromuscular diseases, increase muscle growth and/or muscle strength, or to stimulate vasodilation prior to physical training. Preferred muscular or neuromuscular diseases are m...  
WO/2012/091542
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/092035
Disclosed are methods utilizing beta-hydroxy-beta-methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prev...  
WO/2012/091571
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/085586
The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse G1 side effect...  
WO/2012/081570
Provided is a lactam compound or a salt thereof indicated by formula (1), which is a compound with a lactam skeleton or a salt thereof useful as a PPAR activator. [In the formula, the ring Z indicates a condensed hydrocarbon ring or a he...  
WO/2012/079057
A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.  
WO/2012/079057
A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.  
WO/2012/074068
Provided is an amplifier for hematopoietic stem cells and/or hematopoietic precursor cells having utility as a therapeutic method against types of hematopoietic disease, and having utility for improving gene transfer efficiency to the he...  
WO/2012/075462
The present disclosure provides methods for introducing a gene encoding a muscle membrane protein into a cell isolated from a subject to generate a genetically modified cell. The genetically modified cell may be introduced back, e.g., en...  
WO/2012/068981
Disclosed are 6-deoxy-6-thioether-amino acid cyclodextrin derivatives, obtained from condensation of amino acid derivatives with halo-cyclodextrin in the presence of a base. The 6-deoxy-6-thioether-amino acid cyclodextrin derivatives inc...  
WO/2012/067262
The present invention provides a therapeutic agent for diseases associated with skeletal muscle degeneration, which comprises a granular colony stimulation factor (G-CSF) as an active ingredient. This therapeutic agent is particularly ef...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/058220
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/058220
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/054530
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/053994
The present disclosure relates to ecdysteroid analogues which have similar, identical, or enhanced biological activities as compared to brassinosteroids, for instance similar, identical, or enhanced plant growth promoting activity. The e...  
WO/2012/053012
The present invention relates to stable pharmaceutical compositions of thiocolchicoside comprising nano size droplets of thiocolchicoside or salts thereof along with other pharmaceutically acceptable excipients. The present invention als...  
WO/2012/054527
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/054535
The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or p...  
WO/2012/054528
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/053994
The present disclosure relates to ecdysteroid analogues which have similar, identical, or enhanced biological activities as compared to brassinosteroids, for instance similar, identical, or enhanced plant growth promoting activity. The e...  
WO/2012/053012
The present invention relates to stable pharmaceutical compositions of thiocolchicoside comprising nano size droplets of thiocolchicoside or salts thereof along with other pharmaceutically acceptable excipients. The present invention als...  
WO/2012/044783
The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determini...  
WO/2012/043393
[Problem] To provide an emulsion composition, an external skin preparation, and an analgesic, each of which is in a semi-solid state, has excellent thermal stability, and gives a good use sensation when applied to the skin. [Solution] An...  
WO/2012/043808
The purpose of the present invention is to provide: a heat shock protein expression inducer capable of inducing the in-vivo expression of HSP; food, drink, a pharmaceutical product, and a cosmetic containing the HSP expression inducer; a...  
WO/2012/039472
The purpose of the present invention is to provide a novel method which has an effect of ameliorating central nervous system inflammation. Provided is a drug against central nervous system inflammation which comprises a plasmalogen. Part...  
WO/2012/037083
A method of treating a musculoskeletal injury in a subject includes administering directly to a site of the musculoskeletal injury or to an area proximate the musculoskeletal injury an amount of SDF-1, MCP-3, or combinations thereof effe...  
WO/2012/036168
A composition that is for treating muscular dystrophy and that contains a SIRT1 activating factor as the active ingredient is provided. The composition may further contain a factor that imports SIRT1 to the nucleus. The present invention...  
WO/2012/034201
The present invention relates to a creatine-containing food supplement and method for preparing same. More specifically, the present invention relates to a creatine-containing food supplement formulation compressed into chewable and pala...  
WO/2012/036152
The present invention provides a high purity heparin useful as a medicine, a cosmetic, a research reagent and the like, and a production method therefor, in more detail, a method for producing heparin, the method comprising mixing a hepa...  
WO/2012/037083
A method of treating a musculoskeletal injury in a subject includes administering directly to a site of the musculoskeletal injury or to an area proximate the musculoskeletal injury an amount of SDF-1, MCP-3, or combinations thereof effe...  
WO/2012/033070
[Problem] To provide a pharmaceutical product, especially a pharmaceutical composition which is useful for the treatment of pain. [Solution] The inventors have intensively studied using pain model animals for the purpose of providing a t...  
WO/2012/029994
The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.  
WO/2012/030919
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscl...  
WO/2012/030919
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscl...  
WO/2012/029986
Disclosed is a drug which efficiently allows skipping of the 53rd exon in the human dystrophin gene. Disclosed is an oligomer which makes possible skipping of the 53rd exon of the human dystrophin gene.  

Matches 251 - 300 out of 5,963